Current Diabetes Reports

, Volume 2, Issue 6, pp 545–552 | Cite as

Appropriate drug therapy for improving outcomes in diabetic nephropathy

  • Robert D. Toto


Diabetic nephropathy is the leading cause of end-stage kidney disease in the United States. The majority of these cases are attributed to those with type 2 diabetes. Elevated blood pressure, proteinuria, and increased activity of the renin-angiotensin-aldosterone system (RAAS) play a major role in the development and progression of chronic kidney disease attributed to diabetes mellitus. Moreover, drugs that inhibit angiotensin II synthesis or block the angiotensin II type 1 receptor lower blood pressure, reduce proteinuria, and improve outcomes in patients with chronic kidney disease caused by diabetes. This article highlights improvements in the current management of diabetic nephropathy afforded by agents that inhibit the RAAS, discusses their limitations, and considers novel strategies to prevent onset and progression of diabetic nephropathy. Current opinions concerning combination drug therapy with agents that block the RAAS at multiple sites, as well as combining calcium channel blockers with either angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists, are also discussed.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    USRDS 2001 Annual Data Report. 12th Annual Report. 6-10-0200. Bethesda, MD: U.S. Renal Data System, National Institute of Diabetes and Digestive and Kidney Diseases; 2001.Google Scholar
  2. 2.
    Lewis EJ, Hunsicker L, Bain R, et al.: The Effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993, 329:1456–1462.PubMedCrossRefGoogle Scholar
  3. 3.
    Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851–860.PubMedCrossRefGoogle Scholar
  4. 4.
    Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869. Describes the results of a large-scale, long-term placebo-controlled randomized double-blind clinical trial in type 2 diabetic patients with overt nephropathy. The study demonstrated greater renal benefit and reduced first hospitalization for congestive heart failure in those treated with the angiotensin II receptor antagonist losartan as compared with placebo. These benefits were beyond the bloodpressure-lowering effect of losartan.PubMedCrossRefGoogle Scholar
  5. 5.
    Deckert T, Yokoyama H, Mathiesen E, et al.: Cohort study of predictive value of urinary albumin excretion for atherosclerotic vascular disease in patients with insulin dependent diabetes. BMJ 1996, 312:871–874.PubMedGoogle Scholar
  6. 6.
    Wang SL, Head J, Stevens L, Fuller JH: Excess mortality and its relation to hypertension and proteinuria in diabetic patients. The world health organization multinational study of vascular disease in diabetes. Diabetes Care 1996, 19:305–312.PubMedCrossRefGoogle Scholar
  7. 7.
    Pugh JA, Stern MP, Haffner S, et al.: Excess incidence of treatment of ESRD in Mexican Americans. Am J Epidemiol 1998, 127:135–144.Google Scholar
  8. 8.
    Nelson RG, Bennett PH, Beck GJ, et al.: Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med 1996, 335:1636–1642.PubMedCrossRefGoogle Scholar
  9. 9.
    Cowie CC, Port FK, Wolfe RA, et al.: Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Eng J Med 1989, 321:1074–1079.CrossRefGoogle Scholar
  10. 10.
    Burns KD: Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis 2000, 36:449–467.PubMedGoogle Scholar
  11. 11.
    Miller JA: Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus. J Am Soc Nephrol 1999, 10:1778–1785.PubMedGoogle Scholar
  12. 12.
    Price DA, Porter LE, Gordon M, et al.: The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 1999, 10:2382–2391.PubMedGoogle Scholar
  13. 13.
    Hostetter TH, Rennke HG, Brenner BM: The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982, 72:375–380.PubMedCrossRefGoogle Scholar
  14. 14.
    O’Bryan GT, Hostetter TH: The renal hemodynamic basis of diabetic nephropathy. Semin Nephrol 1997, 17:93–100.PubMedGoogle Scholar
  15. 15.
    Ibrahim HN, Rosenberg ME, Hostetter TH: Role of the reninangiotensin-aldosterone system in the progression of renal disease: a critical review. Semin Nephrol 1997, 17:431–440.PubMedGoogle Scholar
  16. 16.
    Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986, 77:1993–2000.PubMedCrossRefGoogle Scholar
  17. 17.
    Taal MW, Brenner BM: Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int 2000, 57:1803–1817.PubMedCrossRefGoogle Scholar
  18. 18.
    Junaid A, Rosenberg ME, Hostetter TH: Interaction of angiotensin II and TGF-beta 1 in the rat remnant kidney. J Am Soc Nephrol 1997, 8:1732–1738.PubMedGoogle Scholar
  19. 19.
    Chen S, Hong SW, Iglesias-de la Cruz MC, et al.: The key role of the transforming growth factor-beta system in the pathogenesis of diabetic nephropathy. Ren Fail 2001, 23:471–481.PubMedCrossRefGoogle Scholar
  20. 20.
    Ziyadeh FN, Hoffman BB, Han DC, et al.: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 2000, 97:8015–8020.PubMedCrossRefGoogle Scholar
  21. 21.
    Yamamoto T, Nakamura T, Noble NA, et al.: Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A 1993, 90:1814–1818.PubMedCrossRefGoogle Scholar
  22. 22.
    Nakamura S, Nakamura I, Ma L, et al.: Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int 2000, 58:251–259.PubMedCrossRefGoogle Scholar
  23. 23.
    Fogo AB: The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis. Am J Kidney Dis 2000, 35:179–188.PubMedGoogle Scholar
  24. 24.
    Brown NJ, Agirbasli MA, Williams GH, et al.: Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 1998, 32:965–971.PubMedGoogle Scholar
  25. 25.
    Cooper ME: Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001, 44:1957–1972.PubMedCrossRefGoogle Scholar
  26. 26.
    Kumar A, Hawkins KS, Hannan MA, Ganz MB: Activation of PKC-beta(I) in glomerular mesangial cells is associated with specific NF-kappaB subunit translocation. Am J Physiol Renal Physiol 2001, 281:F613-F619.PubMedGoogle Scholar
  27. 27.
    Mezzano SA, Barria M, Droguett MA, et al.: Tubular NF-kappaB and AP-1 activation in human proteinuric renal disease. Kidney Int 2001, 60:1366–1377.PubMedCrossRefGoogle Scholar
  28. 28.
    Toto R: Angiotensin II subtype 1 receptor blockers and renal function. Arch Intern Med 2001, 161:1492–1499.PubMedCrossRefGoogle Scholar
  29. 29.
    Bennett PH, Haffner S, Kasiske BL, et al.: Diabetic renal disease recommendations. Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am J Kid Dis 1995, 25:107–112.PubMedGoogle Scholar
  30. 30.
    Houlihan CA, Tsalamandris C, Akdenis A, Jerums G: Albumin to creatinine ratio: a screening test with limitations. Am J Kidney Dis 2002, 39:1183–1189.PubMedCrossRefGoogle Scholar
  31. 31.
    Borch-Johnsen K, Andersen PK, Deckert T: The effect of proteinuria on the relative mortality in type 1 (insulindependent) diabetes mellitus. Diabetologia 1985, 28:590–596.PubMedCrossRefGoogle Scholar
  32. 32.
    Nelson RG, Meyer TW, Myers BD, Bennett PH: Course of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Kidney Int Suppl 1997, 63:S45-S48.PubMedGoogle Scholar
  33. 33.
    Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, et al.: Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999, 19:1992–1997.PubMedGoogle Scholar
  34. 34.
    Hunsicker LG, Adler S, Caggiula A, et al.: Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997, 51:1908–1919.PubMedCrossRefGoogle Scholar
  35. 35.
    Klahr S, Levey A, Beck G, et al.: The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med 1994, 330:877–884.PubMedCrossRefGoogle Scholar
  36. 36.
    Peterson JC, Adler S, Burkart JM, et al.: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995, 123:754–762.PubMedGoogle Scholar
  37. 37.
    Ruggenenti P, Perna A, Gherardi G, et al.: Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 2000, 35:1155–1165.PubMedGoogle Scholar
  38. 38.
    Ruggenenti P, Perna A, Mosconi L, et al.: Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney Int Suppl 1997, 63:S54-S57.PubMedGoogle Scholar
  39. 39.
    Ecder T, Chapman AB, Brosnahan GM, et al.: Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2000, 35:427–432.PubMedGoogle Scholar
  40. 40.
    Austin SM, Lieberman JS, Newton LD, et al.: Slope of serial glomerular filtration rate and the progression of diabetic glomerular disease. J Am Soc Nephrol 1993, 3:1358–1370.PubMedGoogle Scholar
  41. 41.
    Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators [no authors listed]. Lancet 2000, 355:253–259. Shows the results of a multicenter placebo-controlled trial in more than 3000 type 2 diabetic patients demonstrating that ramipril lowered cardiovascular morbidity and mortality. In a subgroup of almost 1200 microalbuminuric participants, ramipril treatment resulted in a 24% risk reduction for progression from microalbuminuria to overt nephropathy.Google Scholar
  42. 42.
    Toto RD, Adams-Huet B, Fenves AZ, et al.: Effect of ramipril on blood pressure and protein excretion rate in normotensive nondiabetic patients with proteinuria. Am J Kidney Dis 1996, 28:832–840.PubMedGoogle Scholar
  43. 43.
    Bakris GL, Weir MR, DeQuattro V, McMahon FG: Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998, 54:1283–1289.PubMedCrossRefGoogle Scholar
  44. 44.
    Ravid M, Savin H, Jutrin I, et al.: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993, 118:577–581.PubMedGoogle Scholar
  45. 45.
    Jafar TH, Schmid CH, Landa M, et al.: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med 2001, 135:73–87.PubMedGoogle Scholar
  46. 46.
    Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 [no authors listed]. BMJ 1998, 317:703–713.Google Scholar
  47. 47.
    Adler AI, Stratton IM, Neil HA, et al.: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000, 321:412–419.PubMedCrossRefGoogle Scholar
  48. 48.
    Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351:1755–1762.PubMedCrossRefGoogle Scholar
  49. 49.
    Estacio RO, Jeffers BW, Hiatt WR, et al.: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998, 338:645–652.PubMedCrossRefGoogle Scholar
  50. 50.
    Burton C, Harris KP: The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis 1996, 27:765–775.PubMedGoogle Scholar
  51. 51.
    Lewis JB, Berl T, Bain RP, et al.: Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group. Am J Kidney Dis 1999, 34:809–817.PubMedGoogle Scholar
  52. 52.
    Parving HH: Diabetic nephropathy: prevention and treatment. Kidney Int 2001, 60:2041–2055.PubMedCrossRefGoogle Scholar
  53. 53.
    Parving HH, Rossing P, Hommel E, Smidt UM: Angiotensinconverting enzyme inhibition in diabetic nephropathy: ten years’ experience. Am J Kidney Dis 1995, 26:99–107.PubMedGoogle Scholar
  54. 54.
    Nielsen FS, Rossing P, Gall MA, et al.: Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1997, 46:1182–1188.PubMedCrossRefGoogle Scholar
  55. 55.
    Hovind P, Rossing P, Tarnow L, et al.: Remission of nephroticrange albuminuria in type 1 diabetic patients. Diabetes Care 2001, 24:1972–1977.PubMedCrossRefGoogle Scholar
  56. 56.
    Bakris GL, Williams M, Dworkin L, et al.: Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000, 36:646–661.PubMedGoogle Scholar
  57. 57.
    Sharma K, Eltayeb BO, McGowan TA, et al.: Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis 1999, 34:818–823.PubMedGoogle Scholar
  58. 58.
    Bjorck S, Mulec H, Johnsen SA, et al.: Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992, 304:339–343.PubMedGoogle Scholar
  59. 59.
    Mathiesen E, Hommel E, Geise J, Parving H: Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 1991, 303:81–86.PubMedGoogle Scholar
  60. 60.
    Andersen S, Tarnow L, Rossing P, et al.: Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000, 57:601–606.PubMedCrossRefGoogle Scholar
  61. 61.
    Nielsen FS, Rossing P, Gall MA, et al.: Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1997, 46:1182–1188.PubMedCrossRefGoogle Scholar
  62. 62.
    Lacourciere Y, Nadeau A, Poirier L, Tancrede G: Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis. Hypertension 1993, 21:786–794.PubMedGoogle Scholar
  63. 63.
    Parving HH, Lehnert H, Brochner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870–878. Illustrates the results of a multicenter placebo-controlled doubleblind randomized trial in 590 type 2 diabetic patients with hypertension and microalbuminuria followed for 2 years. Irbesartan 300 mg given once daily resulted in a 70% risk reduction for the development of overt nephropathy beyond blood pressure lowering.PubMedCrossRefGoogle Scholar
  64. 64.
    Bakris GL, Copley JB, Vicknair N, et al.: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996, 50:1641–1650.PubMedCrossRefGoogle Scholar
  65. 65.
    Smith AC, Toto R, Bakris GL: Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 1998, 54:889–896.PubMedCrossRefGoogle Scholar
  66. 66.
    Agodoa LY, Appel L, Bakris GL, et al.: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001, 285:2719–2728.PubMedCrossRefGoogle Scholar
  67. 67.
    Staessen J, Lijnen P, Fagard R, et al.: Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981, 91:457–465.PubMedCrossRefGoogle Scholar
  68. 68.
    Komine N, Khang S, Wead LM, et al.: Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels. Am J Kidney Dis 2002, 39:159–164.PubMedGoogle Scholar
  69. 69.
    Bakris GL, Siomos M, Richardson D, et al.: ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int 2000, 58:2084–2092.PubMedCrossRefGoogle Scholar
  70. 70.
    Mogensen CE, Neldam S, Tikkanen I, et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and noninsulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000, 321:1440–1444.PubMedCrossRefGoogle Scholar
  71. 71.
    Russo D, Pisani A, Balletta MM, et al.: Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999, 33:851–856.PubMedGoogle Scholar
  72. 72.
    Agarwal R: Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 2001, 59:2282–2289.PubMedGoogle Scholar
  73. 73.
    Nakao N, Takada M, Yoshimura A, Ideura T: Combination therapy of ACE inhibitor and A-II receptor blocker more powerfully retard progression of non-diabetic renal failure than monotherapy of each drug—a multicenter, four year, double-blind, randomized trial in Japan. J Am Soc Nephrol 2001, 12:231A.Google Scholar

Copyright information

© Current Science Inc. 2002

Authors and Affiliations

  • Robert D. Toto
    • 1
  1. 1.Department of MedicineUniversity of Texas Southwestern Medical Center at DallasDallasUSA

Personalised recommendations